Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: DprE1 inhibitor therapeutics - UniQuest

Next Previous
Search
Drug Profile

Research programme: DprE1 inhibitor therapeutics - UniQuest

Alternative Names: BTZ043

Latest Information Update: 28 Sep 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Queensland
  • Developer UniQuest; University of Queensland
  • Class Antituberculars; Benzothiadiazines; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for preclinical development in Tuberculosis in Australia
  • 04 Aug 2016 Research programme: DprE1 inhibitor therapeutics - UniQuest is available for licensing -https://www.nlm.nih.gov/cgi/mesh/2013/MB_cgi?mode=&index=245645&field=all&HM=&II=&PA=&form=&input=
  • 04 Aug 2016 Preclinical trials in Tuberculosis in Australia (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top